AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37097739 — intervention group
Group type: EXPERIMENTAL
Intervention: iCBT
Number of subjects: 182
Study 37097739 — intervention group
Group type: COMPARATOR
Intervention: WLC
Number of subjects: 182
Study 37097894 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 851
Study 37097894 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab 40 mg
Number of subjects: 851
Study 37097894 — intervention group
Group type: EXPERIMENTAL
Intervention: Both secukinumab and adalimumab
Number of subjects: 851
Study 37097898 — intervention group
Group type: EXPERIMENTAL
Intervention: SND score based on clinical and radiological factors (age >60 years, prehospital or admission arterial hypotension, frontal contusion, Marshall CT score of 6)
Number of subjects: 142
Study 37097898 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >60 years
Number of subjects: 142
Study 37097898 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain frontal contusion
Number of subjects: 142
Study 37097898 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital or admission arterial hypotension
Number of subjects: 142
Study 37097898 — intervention group
Group type: EXPERIMENTAL
Intervention: Marshall CT score of 6
Number of subjects: 142
Study 37097924 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate intake measured using 24-hour dietary recalls (SPRING) or Food Frequency Questionnaire (BABI)
Number of subjects: 281
Study 37097924 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding status added to the model
Number of subjects: 281
Study 37097924 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemic index
Number of subjects: 281
Study 37097986 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung recruitment assessed by electrical impedance tomography
Number of subjects: 0
Study 37098004 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched chain amino acids (BCAA) intake measured in grams (g) per 1000 kilocalories (kcal) of energy intake (range 3.0-34.8 g/1000 kcal)
Number of subjects: 656
Study 37098004 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA modeled as a ratio of BCAA to total protein intake
Number of subjects: 656
Study 37098004 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute BCAA intake
Number of subjects: 656
Study 37098004 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA intake
Number of subjects: 656
Study 37098131 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (25 mg for 4 weeks)
Number of subjects: 11
Study 37098131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 37098173 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Lavender Essential Oil (SLEO)
Number of subjects: 53
Study 37098173 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex Lavender Essential Oil (CLEO)
Number of subjects: 53
Study 37098232 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotorasib
Number of subjects: 0
Study 37098232 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37098399 — intervention group
Group type: EXPERIMENTAL
Intervention: Franseen needle
Number of subjects: 114
Study 37098399 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-prong asymmetric-tip needle
Number of subjects: 114
Study 37098409 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg prucalopride for 6 days
Number of subjects: 50
Study 37098453 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin gel
Number of subjects: 307
Study 37098453 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 307
Study 37098468 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised Mentor Mother services (INT)
Number of subjects: 309
Study 37098468 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 309
Study 37098468 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (INT and SC)
Number of subjects: 309
Study 37098469 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with NDPH
Number of subjects: 29
Study 37098469 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 29
Study 37098492 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative hypothermia
Number of subjects: 742
Study 37098492 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative hypothermia
Number of subjects: 742
Study 37098492 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative hypothermia
Number of subjects: 742
Study 37098492 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA physical status III-IV
Number of subjects: 742
Study 37098494 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) 45 Gy in 5 fractions given every 3-4 days
Number of subjects: 0
Study 37098506 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment approaches for problem gambling
Number of subjects: 800
Study 37098506 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and assessment procedure for problem gambling
Number of subjects: 800
Study 37098506 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic screening for problem gambling at admission and every 6 months thereafter
Number of subjects: 800
Study 37098529 — intervention group
Group type: EXPERIMENTAL
Intervention: Olipudase alfa enzyme replacement therapy
Number of subjects: 5
Study 37098852 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF)
Number of subjects: 268
Study 37098852 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 268
Study 37099132 — intervention group
Group type: EXPERIMENTAL
Intervention: CLDN18.2 functional diagnostic PET imaging
Number of subjects: 0
Study 37099252 — intervention group
Group type: EXPERIMENTAL
Intervention: FundoRingOAGB (f-OAGB)
Number of subjects: 100
Study 37099252 — intervention group
Group type: COMPARATOR
Intervention: Standard OAGB (s-OAGB)
Number of subjects: 100
Study 37099280 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreduction plus HIPEC with mitomycin C (30 mg/m2 over 60 minutes)
Number of subjects: 184
Study 37099280 — intervention group
Group type: COMPARATOR
Intervention: Cytoreduction alone
Number of subjects: 184
Study 37099280 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreduction plus HIPEC with mitomycin C (30 mg/m2 over 60 minutes) in pT4 subgroup
Number of subjects: 184
Study 37099280 — intervention group
Group type: COMPARATOR
Intervention: Cytoreduction alone in pT4 subgroup
Number of subjects: 184
Study 37099283 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 6263
Study 37099283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6263
Study 37099295 — intervention group
Group type: EXPERIMENTAL
Intervention: IM tixagevimab-cilgavimab (300 mg IV or 600 mg IM)
Number of subjects: 348
Study 37099295 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tixagevimab-cilgavimab (300 mg IV)
Number of subjects: 348
Study 37099295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study 37099298 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated low-level red light (RLRL) therapy, twice per day, 5 days per week, each session lasting 3 minutes.
Number of subjects: 139
Study 37099298 — intervention group
Group type: EXPERIMENTAL
Intervention: RLRL therapy (for those without treatment interruption due to COVID-19).
Number of subjects: 139
Study 37099298 — intervention group
Group type: EXPERIMENTAL
Intervention: RLRL therapy
Number of subjects: 139
Study 37099298 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual activities)
Number of subjects: 139
Study 37099299 — intervention group
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 vaccine
Number of subjects: 2247
Study 37099299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2247
Study 37099341 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG-Denmark vaccine
Number of subjects: 3988
Study 37099341 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 3988
Study 37099363 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital messaging therapy
Number of subjects: 24
Study 37099364 — intervention group
Group type: EXPERIMENTAL
Intervention: Social network-based HIV self-test approach
Number of subjects: 463
Study 37099367 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based case management service
Number of subjects: 344
Study 37099367 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 344
Study 37099376 — intervention group
Group type: EXPERIMENTAL
Intervention: TreadWill (unguided computerized cognitive behavioral therapy)
Number of subjects: 598
Study 37099376 — intervention group
Group type: COMPARATOR
Intervention: Full-featured version of TreadWill
Number of subjects: 598
Study 37099498 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Neck Disability Index (NDI) scores
Number of subjects: 97
Study 37099498 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Numeric Pain Rating Scale (NPRS) scores
Number of subjects: 97
Study 37099498 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction term of sex x z-NPRS
Number of subjects: 97
Study 37099498 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline NDI in males
Number of subjects: 97
Study 37099498 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline NPRS in females
Number of subjects: 97
Study 37099511 — intervention group
Group type: EXPERIMENTAL
Intervention: North Star Ambulatory Assessment (NSAA)
Number of subjects: 0
Study 37099511 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient and parent perception using participant-tailored questionnaires
Number of subjects: 0
Study 37099652 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents Taking Action (PTA) intervention
Number of subjects: 15
Study 37099733 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy
Number of subjects: 254
Study 37099733 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers (PD-L1 CPS, CD8, sTIL, TMB, etc.)
Number of subjects: 254
Study 37099736 — intervention group
Group type: EXPERIMENTAL
Intervention: Adagrasib (600 mg orally twice daily)
Number of subjects: 64
Study 37099777 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound (EUS)
Number of subjects: 102
Study 37099777 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound (EUS) and Magnetic Resonance Imaging (MRI)
Number of subjects: 102
Study 37099968 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT + brexpiprazole 2-3 mg/day
Number of subjects: 579
Study 37099968 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT + brexpiprazole 0.5-3 mg/day
Number of subjects: 579
Study 37099968 — intervention group
Group type: COMPARATOR
Intervention: ADT + placebo
Number of subjects: 579
Study 37099983 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene
Number of subjects: 752
Study 37099983 — intervention group
Group type: COMPARATOR
Intervention: Vaginal moisturizers
Number of subjects: 752
Study 37099983 — intervention group
Group type: COMPARATOR
Intervention: Local estrogen therapy
Number of subjects: 752
Study 37100060 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAR2 genetic ablation from vascular endothelial cells
Number of subjects: 0
Study 37100060 — intervention group
Group type: COMPARATOR
Intervention: ADAR2 presence in endothelium
Number of subjects: 0
Study 37100160 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy (hypo-RT) followed by hypofractionated boost (hypo-boost) combined with concurrent weekly chemotherapy (docetaxel 25 mg/m2)
Number of subjects: 75
Study 37100187 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine 80 mg daily
Number of subjects: 180
Study 37100187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 37100205 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning-based immune phenotyping (ML-derived immune phenotypes)
Number of subjects: 934
Study 37100205 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent KEAP1 and STK11 mutations in lung adenocarcinoma (LUAD)
Number of subjects: 934
Study 37100202 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve stimulation (PNS)
Number of subjects: 2
Study 37100202 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 2
Study 37100349 — intervention group
Group type: EXPERIMENTAL
Intervention: 250-mg 17-hydroxyprogesterone caproate
Number of subjects: 159
Study 37100349 — intervention group
Group type: EXPERIMENTAL
Intervention: 500-mg 17-hydroxyprogesterone caproate
Number of subjects: 159
Study 37100349 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of 17-hydroxyprogesterone caproate
Number of subjects: 159
Study 37100349 — intervention group
Group type: EXPERIMENTAL
Intervention: Postenrollment cerclage
Number of subjects: 159
Study 37100349 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial cervical length
Number of subjects: 159
Study 37100424 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-onset pectus excavatum (PE)
Number of subjects: 18
Study 37100424 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral for genetic counseling
Number of subjects: 18
Study 37100486 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive management
Number of subjects: 4617
Study 37100486 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 4617
Study 37100536 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure hospitalization (HHF) or HF death
Number of subjects: 12124
Study 37100536 — intervention group
Group type: COMPARATOR
Intervention: Fatal and nonfatal stroke/systemic embolic events (SEE)
Number of subjects: 12124
Study 37100536 — intervention group
Group type: COMPARATOR
Intervention: Major bleeding (MB)
Number of subjects: 12124
Study 37100536 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure hospitalization (HHF) or HF death in HFrEF vs HFpEF
Number of subjects: 12124
Study 37100536 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality after HHF
Number of subjects: 12124
Study 37100536 — intervention group
Group type: COMPARATOR
Intervention: Mortality after stroke/SEE
Number of subjects: 12124
Study 37100536 — intervention group
Group type: COMPARATOR
Intervention: Mortality after MB
Number of subjects: 12124
Study 37100687 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine intake <150 μg/d
Number of subjects: 93
Study 37100687 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine intake >550 μg/d
Number of subjects: 93
Study 37100687 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iodine intake at zero balance
Number of subjects: 93
Study 37100687 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine intake at zero balance with adequate iodine nutrition
Number of subjects: 93
Study 37100687 — intervention group
Group type: EXPERIMENTAL
Intervention: Calculated recommended nutrient intake (RNI)
Number of subjects: 93
Study 37100687 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine intakes <150 μg/d and >550 μg/d
Number of subjects: 93
Study 37100705 — intervention group
Group type: COMPARATOR
Intervention: 2-week placebo modulator study
Number of subjects: 1791
Study 37100705 — intervention group
Group type: COMPARATOR
Intervention: 6-month placebo modulator study
Number of subjects: 1791
Study 37100705 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week active-comparator modulator study
Number of subjects: 1791
Study 37100705 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month active-comparator modulator study
Number of subjects: 1791
Study 37100705 — intervention group
Group type: COMPARATOR
Intervention: 2-week placebo inhaled antimicrobial study
Number of subjects: 1791
Study 37100705 — intervention group
Group type: COMPARATOR
Intervention: 6-month placebo inhaled antimicrobial study
Number of subjects: 1791
Study 37100821 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with HFmrEF
Number of subjects: 1691
Study 37100869 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery-competing task intervention (immediate access)
Number of subjects: 75
Study 37100869 — intervention group
Group type: COMPARATOR
Intervention: Delayed access to the imagery-competing task intervention (after 4 weeks)
Number of subjects: 75
Study 37100891 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer daily eating window
Number of subjects: 118
Study 37100891 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter time from midsleep point to first food intake
Number of subjects: 118
Study 37100891 — intervention group
Group type: COMPARATOR
Intervention: Meal timing
Number of subjects: 118
Study 37101143 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller meal portions
Number of subjects: 96
Study 37101143 — intervention group
Group type: COMPARATOR
Intervention: Larger meal portions
Number of subjects: 96
Study 37101228 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupuncture regimen (15 sessions combining needling into body acupoints and acupressure on auricular acupoints)
Number of subjects: 138
Study 37101228 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupuncture regimen
Number of subjects: 138
Study 37101228 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture control
Number of subjects: 138
Study 37101251 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant use (primarily meth)
Number of subjects: 25
Study 37101251 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant use
Number of subjects: 25
Study 37101272 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen therapy (HFNC-O)
Number of subjects: 141
Study 37101272 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 141
Study 37101521 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly fremanezumab
Number of subjects: 588
Study 37101521 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly fremanezumab
Number of subjects: 588
Study 37101521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 588
Study 37101768 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdafitinib (8 mg/d continuous in 28-d cycles, uptitration to 9 mg/d if serum phosphate <5.5 mg/dl)
Number of subjects: 101
Study 37101774 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture-based prophylaxis
Number of subjects: 0
Study 37101774 — intervention group
Group type: COMPARATOR
Intervention: Empirical ciprofloxacin prophylaxis
Number of subjects: 0
Study 37101983 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal dexamethasone
Number of subjects: 84
Study 37101983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 37102010 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 40
Study 37102010 — intervention group
Group type: COMPARATOR
Intervention: Control (non-lasered T2DM patients)
Number of subjects: 40
Study 37102392 — intervention group
Group type: EXPERIMENTAL
Intervention: Limosilactobacillus reuteri and omega-3 (ω-3) polyunsaturated fatty acids (PUFAs) supplementation
Number of subjects: 120
Study 37102392 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 120
Study 37102399 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental infection with ETEC
Number of subjects: 9
Study 37102399 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocyte response analysis
Number of subjects: 9
Study 37102399 — intervention group
Group type: EXPERIMENTAL
Intervention: CD56dim CD16 lymphocyte response
Number of subjects: 9
Study 37102600 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype investigational device
Number of subjects: 29
Study 37102598 — intervention group
Group type: EXPERIMENTAL
Intervention: KCd (weekly carfilzomib 70 mg/m2, cyclophosphamide, and dexamethasone)
Number of subjects: 197
Study 37102598 — intervention group
Group type: COMPARATOR
Intervention: Kd (carfilzomib and dexamethasone)
Number of subjects: 197
Study 37102598 — intervention group
Group type: EXPERIMENTAL
Intervention: KCd (in lenalidomide-refractory population)
Number of subjects: 197
Study 37102598 — intervention group
Group type: COMPARATOR
Intervention: Kd (in lenalidomide-refractory population)
Number of subjects: 197
Study 37102598 — intervention group
Group type: COMPARATOR
Intervention: KCd and Kd (overall response rate)
Number of subjects: 197
Study 37102598 — intervention group
Group type: COMPARATOR
Intervention: KCd and Kd (safety profile)
Number of subjects: 197
Study 37102974 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination diuretic therapy (loop diuretics with an add-on agent)
Number of subjects: 0
Study 37102974 — intervention group
Group type: COMPARATOR
Intervention: Loop diuretics
Number of subjects: 0
Study 37103493 — intervention group
Group type: EXPERIMENTAL
Intervention: StressProffen-CBI (Cognitive Behavioral Therapy Intervention)
Number of subjects: 430
Study 37103493 — intervention group
Group type: EXPERIMENTAL
Intervention: StressProffen-MBI (Mindfulness-Based Intervention)
Number of subjects: 430
Study 37103493 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 430
Study 37103493 — intervention group
Group type: EXPERIMENTAL
Intervention: StressProffen-CBI
Number of subjects: 430
Study 37103493 — intervention group
Group type: EXPERIMENTAL
Intervention: StressProffen-MBI
Number of subjects: 430
Study 37103493 — intervention group
Group type: EXPERIMENTAL
Intervention: StressProffen-CBI and StressProffen-MBI
Number of subjects: 430
Study 37103532 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral GnRH antagonists (elagolix 300 mg twice daily with estradiol 1 mg and norethindrone 0.5 mg; relugolix 40 mg once daily with estradiol 1 mg and norethindrone 0.5 mg)
Number of subjects: 0
Study 37103532 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral GnRH antagonists with menopausal replacement-level steroid hormones
Number of subjects: 0
Study 37103532 — intervention group
Group type: EXPERIMENTAL
Intervention: Linzagolix (under investigation)
Number of subjects: 0
Study 37103536 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation
Number of subjects: 102
Study 37103585 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive endoscopy-guided surgery within 8 h after symptom onset
Number of subjects: 40
Study 37103592 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise and dietary therapy (PED-t)
Number of subjects: 0